Immunogenicity and safety of yeast-derived recombinant hepatitis B vaccine (Heberbiovac HB) in South African children

S Afr Med J. 2004 Apr;94(4):280-1.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III
  • Letter
  • Multicenter Study

MeSH terms

  • Drug Administration Schedule
  • Female
  • Hepatitis B / immunology*
  • Hepatitis B / prevention & control
  • Hepatitis B Vaccines / administration & dosage
  • Hepatitis B Vaccines / adverse effects
  • Hepatitis B Vaccines / immunology*
  • Humans
  • Immunization Programs
  • Infant
  • Male
  • South Africa
  • Vaccines, DNA / administration & dosage
  • Vaccines, DNA / adverse effects
  • Vaccines, DNA / immunology*

Substances

  • Hepatitis B Vaccines
  • Vaccines, DNA
  • heberbiovac-HB